NCT00791310 is a Phase 3 clinical trial of Flucis in Severe Sepsis, sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT00791310?

NCT00791310 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT00791310?

Interventions in NCT00791310: Flucis.

What condition does NCT00791310 study?

NCT00791310 studies Severe Sepsis.

Is NCT00791310 still recruiting?

NCT00791310 is currently status unknown. Last updated 30 December 2010.

Last reviewed 2010-12-30 · How we verify

NCT00791310

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 3b,Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology

Status unknown Phase 3 Last updated 30 December 2010

What this trial tests

Phase 3 trial testing Flucis in Severe Sepsis in 30 participants. Status unknown.

Timeline

1 November 2008

Primary endpoint
1 October 2010

1 October 2010

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 November 2008
Primary completion	1 October 2010
Estimated completion	1 October 2010
Sites	1 location across France

Drugs / interventions tested

Flucis — full drug profile →

Conditions studied

Severe Sepsis — all drugs for Severe Sepsis →

Sponsor

Central Hospital, Nancy, France

Who can join

Adults 18 to 80, any sex, with Severe Sepsis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of TEP exams useful for the diagnosis and/or with therapeutic implications.
Time frame: 28 days

Sponsor's own description

The objective of this pilot study is to estimate a procedure where the biological samples routinely obtained at the site of suspected infection could be guided by the early realization of a TEP with FDG coupled to scanner X, in patients hospitalized in ICU for severe sepsis of unspecified etiology.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Triggering receptor expressed on myeloid cells receptor family modulators: a patent review.
Pelham CJ, Pandya AN, Agrawal DK. · · 2014 · cited 51× · PMID 25363248 · DOI 10.1517/13543776.2014.977865

Verify or expand the search:

Other recruiting trials for Severe Sepsis

Currently open trials in the same condition.

NCT06143137 — Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outco · recruiting
NCT04955210 — A Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children · recruiting
NCT05413343 — Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients · active not recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00791310 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 30 December 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00791310.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing